Active Clinical Trial Studies

For more information:


Clinical Trials

Below is a list of currently active Phase II, III and IV trials. You can also search for a specific clinical trial using the field provided above.

  • Tip-Apex Distance

    The main objective of this study is to evaluate if TAD remains predictive of cutout after intertrochanteric femur fractures fixed with modern cephalomedullary nails.

  • Extreme Nailing of Intra-articular Distal Femur Fractures (OTA 33

    The purpose of this study is to compare the reoperation rate of OTA 33-C2 and C3 distal femur fractures treated with retrograde nail fixation versus locked lateral plating.

  • Quality and Outcomes Registry

    Our objective is to create and implement the Level One Orthopaedics Quality and Outcomes Registry with the purpose of retrpspectively and prospectively reviewing our patients and their outcomes

  • Complications of fibular nailing

    The purpose of this study is to examine complications in a consecutive series of patients undergoing fibular nailing and to determine if any specific risk factors exist for these complications.


    The primary objective is to determine if there is any difference with regard to complication rate for performing surgery on an OR table vs performing surgery on a stretcher with a hand table. Outcome measures will include any complications recorded by patient postoperative questionnaires.

  • Tibotalocalcaneal Retrograde

    The purpose of this study is to identify risk factors for major complications of retrograde intramedullary nail tibiotalocalcaneal arthrodesis in order to help guide treatment decisions.

  • Cephalomedullary Reconstruction

    The objective of this study is to compare implant-related complications and reoperations after standard versus cephalomedullary proximal locking screw fixation of antegrade intramedullary nailing of femoral shaft fractures.

  • Phase 2 of MLN0128 with Fulvestrant with ER-Positive/HER2-

    To compare the PFS of patients treated with the combination of fulvestrant+daily MLN0128 versus patients treated with single-agent fulvestrant.

  • Assessing Accuracy of Tumor Bed Biopsies in Pathologic Response

    To assess the accuracy of post-neoadjuvant systemic therapy (NST) image-directed tumor bed biopsy for pathologic complete response (pCR), defined as resolution of both invasive disease and DCIS in cases of clinical and radiologic complete response with trimodality imaging.

  • Tucatinib for Metastatic HER2+ Breast Carcinoma

    To assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival